Calendrier des promotions Plus Therapeutics, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Plus Therapeutics, Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Paramètres de base
IPO date
2000-11-16
ISIN
US72941H4002
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 1.22 | 9 |
P/BV | -0.9896 | 0 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -144.03 | 0 |
ROE | 252.07 | 10 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.4007 | 10 |
Debt/Ratio | 0.5076 | 9 |
Debt/Equity | -1.74 | 10 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | 63.77 | 8 |
Rentabilité Ebitda, % | -8.67 | 0 |
Rentabilité EPS, % | -94.68 | 0 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 0.31 $ | 0 $ | 0 $ | 1.29 % | 0 % | 0 % |
common.calendar.number_days.7d | 0.33 $ | 0 $ | 0 $ | -4.85 % | 0 % | 0 % |
common.calendar.number_days.30d | 0.3 $ | 0.31 $ | 0.35 $ | 4.67 % | 0 % | 0 % |
common.calendar.number_days.90d | 0.75 $ | 0.27 $ | 0.98 $ | -58.13 % | 0 % | 0 % |
common.calendar.number_days.180d | 1.24 $ | 0.27 $ | 1.57 $ | -74.68 % | 0 % | 0 % |
common.calendar.number_days.1y | 1.43 $ | 0.27 $ | 1.9 $ | -78.04 % | 0 % | 0 % |
common.calendar.number_days.3y | 0.87 $ | 0.27 $ | 7.2 $ | -63.91 % | 0 % | 0 % |
common.calendar.number_days.5y | 2.6 $ | 0.27 $ | 7.2 $ | -87.92 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.13 $ | 0.13 $ | 19.25 $ | 238.46 % | 0 % | 0 % |
common.calendar.number_days.ytd | 1.24 $ | 0.27 $ | 1.57 $ | -74.68 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. Marc H. Hedrick M.B.A., M.D. | President, CEO & Director | 945.34k | 1963 (62 année) |
Mr. Andrew J. Sims CPA | VP of Finance & CFO | 498.51k | 1973 (52 année) |
Ms. Desiree Smith | Corporate Controller, Principal Financial & Accounting Officer | N/A | 1964 (61 année) |
Dr. John K. Fraser | Chief Scientist | N/A | 1961 (64 année) |
Informations sur l'entreprise
Adresse: United States, Austin. TX, 4200 Marathon Boulevard - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://plustherapeutics.com
Site web: https://plustherapeutics.com